Chimeric peptide immunogens
AssigneeAphton Corporation
InventorsStephen Grimes, Dov Michaeli, Vernon C. Stevens
Life of this patent
Estimating the term…
Abstract
Chimeric peptide epitopes can serve as effective immunogens against hormones and other small peptides or proteins. Thus, immunogenic peptides are selected from promiscuous Th epitopes and synthesized together with self antigenic peptide sequences fused with or without end to end spacer peptide interconnections. A peptide sequence which may be of the gonadotropin releasing hormone is linked with an immunogenic peptide sequence selected from a promiscuous Th-epitope of measles virus protein F, tetanus toxoid, or malaria protein CSP. Compositions of the chimeric immunogen are found effective in eliciting high and specific anti-GnRH antibody titers.
Claims14
A synthetic immunogen for inducing specific antibodies against GnRH comprising:
- (i) a promiscuous helper T-lymphocyte epitope selected from the group consisting of SEQ ID NO:
- 8 of measles virus protein F (MVP-F), SEQ ID NO:
- 2, SEQ ID NO:
- 4 of tetanus toxoid (TT), and SEQ ID NO:
- 3 of malaria circumsporozoitc protein (M-CSP), fused through
- (ii) a spacer peptide selected from the group consisting of Gly-Pro-Ser-Leu (SEQ ID NO:
- 5), Ser-Ser-Gly-Pro-Ser-Leu (SEQ ID NO:
- 6), and Ser-Ser-Gly-Pro-Ser-Leu-Lys-Leu (SEQ ID NO:
- 7) to
- (iii) a GnRH immunonmimic peptide comprising either the amino acid sequence of SEQ ID NO:
- 1, or amino acids 2-10 of SEQ ID NO:
- 1.
A synthetic immunogen for inducing specific antibodies against GnRH comprising a promiscuous helper T-lymphocyte epitope fused through a spacer peptide to a GnRH immunomimic peptide selected from the group consisting of the peptide defined by SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, or SEQ ID NO;
- 20.
A combination of synthetic immunogens for inducing specific antibodies against GnRH comprising at least two different synthetic immunogens selected from the group consisting of the peptide defined by SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, SEQ ID NO:
- 13, SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO. 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, or SEQ ID NO:
- 20.
Dependencies are inferred from the claim text.